Navigation Links
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Date:9/18/2007

ith HIV medications and had a viral load greater than 5,000 copies. Overall the study population had a mean baseline viral load of 4.85 log10 copies per mL and a median CD4+ cell count of 225 cells per cubic millimeter.

Patients were randomized to receive PREZISTA/r 800 mg/100 mg once daily (n=343) or, based on approved dosing in each country, either lopinavir/r 800 mg/200 mg once daily or 400 mg/100 mg twice daily (n=346), plus a background regimen of tenofovir and emtricitabine once daily. Patient randomization was stratified based on viral load and CD4+ cell count.

ARTEMIS: 48-week study results

In the per-protocol analysis of 689 patients, among patients randomized to the once-daily PREZISTA/r arm (n=343) vs. the lopinavir/r arm (n=346), the 48-week analysis showed that:

-- 84 percent of patients in the PREZISTA/r arm reached an undetectable

viral load (<50 copies/mL) vs. 78 percent of patients in the

lopinavir/r arm.

-- The median change in CD4+ cell count from baseline was similar between

the PREZISTA/r and lopinavir/r arms (137 cells per cubic millimeter vs.

141 cells per cubic millimeter).

ARTEMIS: Safety findings

-- In the two study arms the adverse events at least Grade 2 in severity

included diarrhea, nausea and rash. Diarrhea was 4.1 percent in the

PREZISTA/r arm vs. 9.8 percent in the lopinavir/r arm. Nausea was 1.7

percent in the PREZISTA/r arm vs. 2.9 percent in the lopinavir/r arm.

Rash was 2.6 percent in the PREZISTA/r arm vs. 1.2 percent in the

lopinavir/r arm.

-- Incidence of Grade 3-4 lipid-related adverse events reported in

PREZISTA/r arm were 1.7 percent vs. 5.2 percent in the lopinavir/r arm.

-- In both treatment arms there was a low incidence of discontinuation.

Discontinuations due to adverse events were 3.4 percent in the

PREZISTA/r arm vs. 6.9 percent in the lopinavir/r arm.


'/>"/>
SOURCE Tibotec Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  With a ... animal health medications, a Global Pharmaceutical and Biotech ... serialization technology and turnkey solution to protect their ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... that was serialized and aggregated by the Xyntek ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
(Date:10/22/2014)... Oct. 22, 2014 Sanomedics International Holdings, Inc. ... by Global Research & Data Services, demand for thermometers ... 2014 through 2018, as demand for more accurate digital ... is the world,s largest market for thermometers, and one ... is Sanomedics International Holdings, Inc. Sanomedics International ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
... Calif., March 22, 2012  SurgiCount Medical, Inc., the ... (OTCBB:PSTX, OTCQB:PSTX) today announced that it will be ... compliance software tool for use with its market ... Congress in New Orleans, March 24th - 28th.  ...
...  Anaphore Inc. today announced that it has acquired Shanghai-based ... discovery platform focused on the discovery and development of ... was founded by Raymond Stevens, PhD., of The Scripps ... of Shanghai, China. "The acquisition of RuiYi ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Functionality of the Safety-Sponge® System 2SurgiCount Medical Announces Expanded Functionality of the Safety-Sponge® System 3Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform 2Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform 3
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... Alexandria, Va., USA During the April 5 White House ... willing to work with leaders in Congress from both political ... week. The President stated that he has matched the initial ... for FY11, with differences existing only in areas of priority. ...
... sets of brothers with autism, Johns Hopkins scientists have ... be linked very specifically to the severity of social ... protein 1), is a blueprint for a traffic-directing protein ... cells across which chemical signals flow. , ...
... at North Carolina State University are narrowing the search ... dogs into humans. Humans and dogs don,t just ... similar genetic makeup. Additionally, they share the same types ... genomics at NC State, uses canines as a genetic ...
... AUGUSTA, Ga. Scientists want to protect the optic nerve when ... car wreck. It,s called traumatic optic nerve damage when the ... rattled, resulting in swelling and inflammation that can destroy its major ... and blindness. "The optic nerve is not completely straight so ...
... may join you as the only animal that can re-grow ... chemical cocktail can coax mouse muscle fibers to become the ... regenerating limb. Their study, the first demonstration that mammal muscle ... new limb, appears in the journal ACS Chemical Biology ...
... ORLANDO, FL (April 6, 2011) Breast cancer is the ... women diagnosed each year. Being exposed to estrogen over a ... a woman,s risk of developing the disease. One way ... the breast cancer drug tamoxifen, which interferes with the activity ...
Cached Medicine News:Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2Health News:Gene linked to severity of autism's social dysfunction 2Health News:Gene linked to severity of autism's social dysfunction 3Health News:Sniffing out lymphoma by turning dogs into humans 2Health News:Better treatment sought for blinding traumatic optic nerve damage 2Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... OMNI~NEB delivers breakthrough continuous low-flow ... and precise nozzle technology allows for ... with or without Heliox). OMNI~NEB takes ... in both routine and critical care ...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
Medicine Products: